You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSalsalate
Accession NumberDB01399
TypeSmall Molecule
GroupsApproved
DescriptionSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Structure
Thumb
Synonyms
2-Carboxyphenyl salicylate
Disalcid
Disalicylic acid
Disalicylsaeure
O-Salicylcylsalicylsaeure
O-Salicylsalicylic acid
Salicylic acid bimolecular ester
Salicyloxysalicylic acid
Salicyloylsalicylic acid
salicylsalicylic acid
Salsalato
Salsalatum
Sasapyrin
Sasapyrine
Sasapyrinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disalcid - Tab 500mgTablet500 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-10-012002-07-09Canada
Disalcid - Tab 750mgTablet750 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-06-012002-07-09Canada
Disalcid Tab 500mgTablet500 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Disalcid Tab 750mgTablet750 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DisalcidTablet750 mg/1OralAvion Pharmaceuticals, Llc2014-09-18Not applicableUs
DisalcidTablet500 mg/1OralAvion Pharmaceuticals, Llc2014-09-18Not applicableUs
SalsalateTablet500 mg/1OralECI Pharmaceuticals, LLC2014-10-01Not applicableUs
SalsalateTablet500 mg/1OralAcella Pharmaceuticals, LLC2011-05-16Not applicableUs
SalsalateTablet750 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.1995-04-01Not applicableUs
SalsalateTablet750 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-09-24Not applicableUs
SalsalateTablet500 mg/1OralMajor Pharmaceuticals1998-08-03Not applicableUs
SalsalateTablet, film coated500 mg/1OralNationwide Laboratories, LLC2011-08-19Not applicableUs
SalsalateTablet750 mg/1OralClinical Solutions Wholesale2010-09-24Not applicableUs
SalsalateTablet750 mg/1OralA S Medication Solutions Llc2010-09-24Not applicableUs
SalsalateTablet500 mg/1OralCarilion Materials Management2010-09-24Not applicableUs
SalsalateTablet750 mg/1OralAv Pak2015-02-18Not applicableUs
SalsalateTablet750 mg/1OralAcella Pharmaceuticals, LLC2011-05-16Not applicableUs
SalsalateTablet, film coated500 mg/1OralBoca Pharmacal, Inc.2012-01-162015-12-29Us
SalsalateTablet750 mg/1OralECI Pharmaceuticals, LLC2014-10-01Not applicableUs
SalsalateTablet750 mg/1OralMajor Pharmaceuticals2004-01-29Not applicableUs
SalsalateTablet750 mg/1Oralbryant ranch prepack1995-04-01Not applicableUs
SalsalateTablet500 mg/1OralAv Pak2014-11-18Not applicableUs
SalsalateTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
SalsalateTablet, film coated750 mg/1OralNationwide Laboratories, LLC2011-08-19Not applicableUs
SalsalateTablet, film coated500 mg/1Oral3 T Federal Solutions Llc2012-01-16Not applicableUs
SalsalateTablet750 mg/1OralCarilion Materials Management2010-09-24Not applicableUs
SalsalateTablet500 mg/1OralAv Kare, Inc.2013-05-172016-02-03Us
SalsalateTablet, film coated750 mg/1OralBoca Pharmacal, Inc.2012-01-162015-12-29Us
SalsalateTablet500 mg/1OralLibertas Pharma, Inc.2011-05-222016-10-13Us
SalsalateTablet, film coated500 mg/1OralMarlex Pharmaceuticals Inc2007-04-01Not applicableUs
SalsalateTablet500 mg/1OralAmneal Pharmaceuticals2010-09-24Not applicableUs
SalsalateTablet750 mg/1OralAv Pak2014-11-18Not applicableUs
SalsalateTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-24Not applicableUs
SalsalateTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-16Not applicableUs
SalsalateTablet, film coated750 mg/1Oral3 T Federal Solutions Llc2012-01-16Not applicableUs
SalsalateTablet750 mg/1OralRebel Distributors Corp1995-04-01Not applicableUs
SalsalateTablet750 mg/1OralAv Kare, Inc.2013-05-172016-02-03Us
SalsalateTablet500 mg/1OralClinical Solutions Wholesale2010-09-24Not applicableUs
SalsalateTablet750 mg/1OralLibertas Pharma, Inc.2011-05-222016-10-13Us
SalsalateTablet, film coated750 mg/1OralMarlex Pharmaceuticals Inc2007-04-01Not applicableUs
SalsalateTablet750 mg/1OralAmneal Pharmaceuticals2010-09-24Not applicableUs
SalsalateTablet500 mg/1OralAv Pak2015-02-18Not applicableUs
SalsalateTablet500 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.1995-04-01Not applicableUs
SalsalateTablet750 mg/1OralAphena Pharma Solutions Tennessee, Inc.2011-05-22Not applicableUs
Salsalate RxTablet, film coated500 mg/1OralAnda Pharm Llc2015-01-01Not applicableUs
Salsalate RxTablet, film coated750 mg/1OralAnda Pharm Llc2015-01-01Not applicableUs
International Brands
NameCompany
DisalcidNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV9MO595C9I
CAS number552-94-3
WeightAverage: 258.2262
Monoisotopic: 258.05282343
Chemical FormulaC14H10O5
InChI KeyWVYADZUPLLSGPU-UHFFFAOYSA-N
InChI
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
IUPAC Name
2-(2-hydroxybenzoyloxy)benzoic acid
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O
Pharmacology
IndicationFor relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.
Structured Indications Not Available
PharmacodynamicsSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.
Mechanism of actionThe mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Related Articles
AbsorptionSalsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.
Volume of distributionNot Available
Protein bindingSalicylate: 90-95% bound at plasma salicylate concentrations <100 mcg/mL; 70-85% bound at concentrations of 100-400 mcg/mL; 25-60% bound at concentrations >400 mcg/mL.
Metabolism

Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body.

Route of eliminationNot Available
Half lifeThe parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
ClearanceNot Available
ToxicityDeath has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Salsalate Action PathwayDrug actionSMP00707
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with 5-androstenedione.Experimental, Illicit
AbciximabSalsalate may increase the anticoagulant activities of Abciximab.Approved
AcebutololSalsalate may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Salsalate is combined with Aceclofenac.Approved
AcenocoumarolSalsalate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salsalate.Approved, Vet Approved
AclarubicinSalsalate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salsalate.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.Approved
AliskirenSalsalate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololSalsalate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salsalate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Amcinonide.Approved
AmikacinSalsalate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSalsalate may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinSalsalate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSalsalate may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Salsalate is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Salsalate is combined with Anisodamine.Investigational
annamycinSalsalate may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.Approved
Antithrombin III humanSalsalate may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Salsalate may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanSalsalate may increase the anticoagulant activities of Apixaban.Approved
ApramycinSalsalate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Salsalate is combined with Apremilast.Approved, Investigational
ArbekacinSalsalate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinSalsalate may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSalsalate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSalsalate may decrease the antihypertensive activities of Arotinolol.Approved
AtenololSalsalate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salsalate.Approved
BalsalazideSalsalate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSalsalate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Salsalate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSalsalate may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Salsalate.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salsalate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Betamethasone.Approved, Vet Approved
BetaxololSalsalate may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Betulinic Acid.Investigational
BevantololSalsalate may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salsalate.Approved, Investigational
BisoprololSalsalate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSalsalate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSalsalate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Salsalate is combined with Bucillamine.Investigational
BucindololSalsalate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Budesonide.Approved
BufuralolSalsalate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideSalsalate may decrease the diuretic activities of Bumetanide.Approved
BupranololSalsalate may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salsalate.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Salsalate.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salsalate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salsalate.Approved, Vet Approved, Withdrawn
CarteololSalsalate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSalsalate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Salsalate is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Celecoxib.Approved, Investigational
CeliprololSalsalate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSalsalate may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salsalate.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salsalate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salsalate.Approved
CinoxacinSalsalate may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinSalsalate may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidSalsalate may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Salsalate is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salsalate.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Salsalate is combined with Curcumin.Investigational
CyclosporineSalsalate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Salsalate is combined with D-Limonene.Investigational
Dabigatran etexilateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSalsalate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSalsalate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinSalsalate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Salsalate is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Salsalate is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinSalsalate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salsalate.Approved
DextranSalsalate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Salsalate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Salsalate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Salsalate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salsalate.Approved, Vet Approved
DicoumarolSalsalate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Salsalate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salsalate.Approved
DihydrostreptomycinSalsalate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Salsalate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salsalate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salsalate.Approved
DoxorubicinSalsalate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSalsalate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Salsalate is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Salsalate is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Salsalate is combined with Ebselen.Investigational
Edetic AcidSalsalate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSalsalate may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Salsalate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salsalate.Approved
EnoxacinSalsalate may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinSalsalate may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Salsalate is combined with Epirizole.Approved
EpirubicinSalsalate may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSalsalate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.Approved
EquileninThe risk or severity of adverse effects can be increased when Salsalate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Salsalate is combined with Equilin.Approved
EsmololSalsalate may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone sulfate.Approved
Etacrynic acidSalsalate may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.Approved, Investigational
Ethyl biscoumacetateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Salsalate is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Salsalate is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Salsalate is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Salsalate is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salsalate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salsalate.Vet Approved
FleroxacinSalsalate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salsalate.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fludrocortisone.Approved
FluindioneSalsalate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSalsalate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Salsalate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Salsalate is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salsalate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Salsalate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salsalate.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salsalate.Approved, Nutraceutical, Vet Approved
FondaparinuxSalsalate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSalsalate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salsalate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Salsalate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salsalate.Approved
FramycetinSalsalate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSalsalate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSalsalate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSalsalate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSalsalate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salsalate.Approved, Withdrawn
GemifloxacinSalsalate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSalsalate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSalsalate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASalsalate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinSalsalate may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Salsalate is combined with HE3286.Investigational
HeparinSalsalate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Salsalate is combined with Higenamine.Investigational
HirulogSalsalate may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Salsalate is combined with HMPL-004.Investigational
HydralazineSalsalate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salsalate.Approved
Hygromycin BSalsalate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Salsalate is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Salsalate is combined with Icatibant.Approved
IdarubicinSalsalate may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxSalsalate may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Salsalate.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.Approved
IndenololSalsalate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Indoprofen.Withdrawn
INNO-206Salsalate may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Salsalate is combined with Istaroxime.Investigational
KanamycinSalsalate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salsalate.Approved
LabetalolSalsalate may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salsalate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salsalate.Approved, Investigational
LepirudinSalsalate may increase the anticoagulant activities of Lepirudin.Approved
LevobunololSalsalate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSalsalate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Salsalate.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salsalate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Salsalate is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Salsalate.Approved
LomefloxacinSalsalate may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salsalate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Salsalate.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salsalate.Approved
ME-609The risk or severity of adverse effects can be increased when Salsalate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salsalate.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Salsalate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.Approved, Vet Approved
MesalazineSalsalate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Salsalate is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salsalate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSalsalate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.Approved
MetoprololSalsalate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSalsalate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salsalate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Salsalate is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Salsalate.Approved
MometasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salsalate.Approved
MoxifloxacinSalsalate may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Nabumetone.Approved
NadololSalsalate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSalsalate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSalsalate may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salsalate.Approved
Nalidixic AcidSalsalate may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salsalate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Salsalate is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Salsalate is combined with NCX 4016.Investigational
NeamineSalsalate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinSalsalate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSalsalate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Salsalate is combined with Nepafenac.Approved
NetilmicinSalsalate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Salsalate is combined with Nitroaspirin.Investigational
NorfloxacinSalsalate may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSalsalate may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salsalate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.Approved
OlsalazineSalsalate may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Salsalate is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Salsalate.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Salsalate is combined with Orgotein.Vet Approved
OtamixabanSalsalate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.Approved
OxprenololSalsalate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Parecoxib.Approved
ParomomycinSalsalate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinSalsalate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSalsalate may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSalsalate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Salsalate.Approved
PhenindioneSalsalate may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonSalsalate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salsalate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.Approved, Investigational
PindololSalsalate may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinSalsalate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSalsalate may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.Approved, Investigational
PlicamycinSalsalate may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salsalate.Approved
PractololSalsalate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salsalate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Salsalate can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Salsalate is combined with Propacetamol.Approved
PropranololSalsalate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salsalate.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Salsalate.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salsalate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Salsalate.Vet Approved
Protein CSalsalate may increase the anticoagulant activities of Protein C.Approved
Protein S humanSalsalate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSalsalate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSalsalate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Salsalate is combined with PTC299.Investigational
PuromycinSalsalate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Salsalate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salsalate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Salsalate.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salsalate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.Experimental, Investigational
ReviparinSalsalate may increase the anticoagulant activities of Reviparin.Approved
RibostamycinSalsalate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.Approved, Investigational
RivaroxabanSalsalate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinSalsalate may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Salsalate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salsalate.Approved, Vet Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salsalate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Salsalate is combined with Seratrodast.Approved, Investigational
SisomicinSalsalate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolSalsalate may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSalsalate may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSalsalate may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSalsalate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Salsalate.Approved
SpironolactoneSalsalate may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Salsalate is combined with SRT501.Investigational
StreptomycinSalsalate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSalsalate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineSalsalate may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salsalate.Approved
SulodexideSalsalate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Salsalate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.Approved, Withdrawn
TacrolimusSalsalate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Salsalate.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salsalate.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salsalate.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.Approved, Investigational
TemafloxacinSalsalate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Salsalate.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Salsalate is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salsalate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Salsalate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Salsalate is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiludronate.Approved, Vet Approved
TimololSalsalate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Salsalate is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Salsalate is combined with Tixocortol.Approved
TobramycinSalsalate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.Approved
TorasemideSalsalate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salsalate.Approved
TranilastThe risk or severity of adverse effects can be increased when Salsalate is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSalsalate may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Salsalate is combined with Trisalicylate-choline.Approved
TrovafloxacinSalsalate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salsalate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinSalsalate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salsalate.Approved
WarfarinSalsalate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSalsalate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Salsalate may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salsalate.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Salsalate is combined with Zomepirac.Withdrawn
ZorubicinSalsalate may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02BA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9161
Blood Brain Barrier+0.8946
Caco-2 permeable+0.5186
P-glycoprotein substrateNon-substrate0.6391
P-glycoprotein inhibitor INon-inhibitor0.8819
P-glycoprotein inhibitor IINon-inhibitor0.9074
Renal organic cation transporterNon-inhibitor0.8788
CYP450 2C9 substrateNon-substrate0.7946
CYP450 2D6 substrateNon-substrate0.9353
CYP450 3A4 substrateNon-substrate0.7281
CYP450 1A2 substrateNon-inhibitor0.7887
CYP450 2C9 inhibitorNon-inhibitor0.5411
CYP450 2D6 inhibitorNon-inhibitor0.9409
CYP450 2C19 inhibitorNon-inhibitor0.8028
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8116
Ames testNon AMES toxic0.9731
CarcinogenicityNon-carcinogens0.8579
BiodegradationReady biodegradable0.5723
Rat acute toxicity2.4607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9607
hERG inhibition (predictor II)Non-inhibitor0.9403
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral500 mg
TabletOral750 mg
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
Prices
Unit descriptionCostUnit
Salsalate powder16.8USD g
Salsalate 750 mg tablet0.55USD tablet
Salflex-750 tablet0.5USD tablet
Salflex-500 tablet0.37USD tablet
Salsalate 500 mg tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.246 mg/mLALOGPS
logP3.44ALOGPS
logP3.64ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.4ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability24.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.76 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassDepsides and depsidones
Sub ClassNot Available
Direct ParentDepsides and depsidones
Alternative Parents
Substituents
  • Depside backbone
  • Salicylic acid or derivatives
  • Phenol ester
  • Benzoate ester
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Carboxylic acid ester
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Stichtenoth DO, Zeidler H, Frolich JC: [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. Med Klin (Munich). 1998 Jul 15;93(7):407-15. [PubMed:9711054 ]
  2. Schaefer MG, Plowman BK, Morreale AP, Egan M: Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23. [PubMed:12901032 ]
  3. Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32. [PubMed:16808554 ]
  4. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. [PubMed:15242723 ]
  2. Schmidt A, Hescheler J, Offermanns S, Spicher K, Hinsch KD, Klinz FJ, Codina J, Birnbaumer L, Gausepohl H, Frank R, et al.: Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991 Sep 25;266(27):18025-33. [PubMed:1680855 ]
  3. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:05 / Updated on August 17, 2016 12:23